Background Convincing data on epidermal growth factor receptor (EGFR) mutations in
Chinese patients with non-small-cell lung cancer (NSCLC) remain limited. We investigated …

The efficacy of gefitinib for patients with non‐adenocarcinoma non‐small‐cell lung cancer
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …

Purpose: Recent studies reported that clinical responsiveness to gefitinib was associated
with somatic mutation of epidermal growth factor receptor (EGFR) gene in non–small cell …

Purpose Our aim was to determine whether abundance of epidermal growth factor receptor
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …

Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …

Background Although activating epidermal growth factor receptor (EGFR) mutations are
excellent predictors of gefitinib outcome in non–small-cell lung cancer (NSCLC), most …

Purpose This study was undertaken to investigate the effects of epidermal growth factor
receptor (EGFR) mutation and its downstream signaling on response and survival in non …

Study objectives The prevalence of epidermal growth factor receptor (EGFR) mutations in
gefitinib-naive lung cancer patients is higher in adenocarcinomas, in women, and in …

Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …

Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …